Brochures

      Scientific Update August 2021 Issue 13

      PMI

      Published on
      Aug 26, 2021
      Link to more information
      Topic
      Summary

      PMI releases its latest Scientific Update 13, a regular publication on its research efforts to further tobacco harm reduction and to develop and assess a range of potentially reduced-risk alternatives to cigarettes.

      The 13th issue of the Scientific Update features an editorial by Steve Roulet, Global Head of Behavioral Research Insights. There, he examines product use patterns, relative risk, and the effects of switching to smoke-free alternatives, compared to continued smoking.

      This issue discusses how switching to scientifically substantiated smoke-free products can reduce the risk of smoking-related harm for individuals and the population as a whole. It also highlights the importance of monitoring use patterns over time to evaluate changes in risk to the population. Another highlight from this issue details our clinical research indicating the short-term health-related improvements that can come from switching completely from cigarettes to PMI’s Heated Tobacco Product, compared to continued smoking.

      This issue of the Scientific Update features an overview of the historic decision made by the U.S. Food and Drug Administration, and update from the ABOUT Toolbox team and an overview of some of our latest publications by PMI and independent researchers.

      Flip through the pages of our latest Scientific Update to learn more.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.